OOIR: Observatory of International Research

Papers

(The H4-Index of mAbs is 36. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Tokenizing loops of antibodies	267
Correction	179
A next-generation Fab library platform directly yielding drug-like antibodies with high affinity, diversity, and developability	175
Development of a novel, high-throughput imaged capillary isoelectric focusing-Western method to characterize charge heterogeneity of monoclonal antibody heavy and light chains	160
Biologics developability data analysis using hierarchical clustering accelerates candidate lead selection, optimization, and preformulation screening	153
CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin’s lymphoma	141
Seq2scFv: a toolkit for the comprehensive analysis of display libraries from long-read sequencing platforms	102
Optimization strategies for monoclonal antibody production: advances in simulation and artificial intelligence in bioprocessing	102
Self-interaction nanoparticle spectroscopy predicts high-concentration viscosity of therapeutic IgG1 antibodies	97
Approaches to expand the conventional toolbox for discovery and selection of antibodies with drug-like physicochemical properties	92
Characterization of anti-SARS-CoV-2 monoclonal antibodies focusing on antigen binding, neutralization, and FcγR activation via formation of immune complex	91
Application of quantitative protein mass spectrometric data in the early predictive analysis of membrane-bound target engagement by monoclonal antibodies	90
An antibody developability triaging pipeline exploiting protein language models	78
Overcoming claudin family homology: discovery of ARC101, a highly potent CLDN6-specific T-cell engager with a novel CD3 binder for ovarian adenocarcinoma	72
Correction	67
The double-edged nature of antibody bivalency: mathematical and experimental analysis of cell surface antigen occupancy and opsonization	65
Izokibep: Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis	59
A window into the human immune system: comprehensive characterization of the complexity of antibody complementary-determining regions in functional antibodies	58
Mechanistic and predictive formulation development for viscosity mitigation of high-concentration biotherapeutics	57
Insight into the avidity–affinity relationship of the bivalent, pH-dependent interaction between IgG and FcRn	56
Selection of target-binding proteins from the information of weakly enriched phage display libraries by deep sequencing and machine learning	55
The emergence of cell-based protein arrays to test for polyspecific off-target binding of antibody therapeutics	51
Setting expectations for current and future directions of native mass spectrometry in the biopharmaceutical industry	48
GlycoVHH: optimal sites for introducing N-glycans on the camelid VHH antibody scaffold and use for macrophage delivery	47
Rapid expression of therapeutic antibodies in mammalian cells via mRNA transfection	46

A highly selective TCR-mimic antibody reveals unexpected mechanisms of HBV peptide-MHC recognition and previously unknown target biology	42
Identification of tyrosine sulfation in the variable region of a bispecific antibody and its effect on stability and biological activity	42
Impact of IgG subclass on monoclonal antibody developability	41
A mouse pancreatic organoid model to compare PD-L1 blocking antibodies	40
The nonglycosylated variant in therapeutic monoclonal antibodies preferentially forms large aggregates under typical thermal stresses used in forced degradation studies	39
Unambiguous identification of α-Gal epitopes in intact monoclonal antibodies by NMR spectroscopy	38
Breaking barriers in antibody discovery: harnessing divergent species for accessing difficult and conserved drug targets	38
Preclinical safety evaluation of the dipeptidyl peptidase 3 inhibiting antibody Procizumab in rodents and non-human primates	38
Optimizing efficacy and safety of T cell bispecific antibodies: the interdependence of CD3 and tumor antigen binder affinities in FOLR1 and CEACAM5 2 + 1 TCBs	37
Simultaneous affinity maturation and developability enhancement using natural liability-free CDRs	36
Antibodies to watch in 2024	36
Navigating large-volume subcutaneous injections of biopharmaceuticals: a systematic review of clinical pipelines and approved products	36